Type 2 diabetes is associated with an increased risk of developing macro and microvascular complications. Nevertheless, there is substantial heterogeneity between people with type 2 diabetes in their risk of developing such complications. Personalised medicine for people with type 2 diabetes may aid in efficient and tailored diabetes care for those at increased risk of developing such complications. Recently, progress has been made in the development of personalised diabetes care in several areas. Particularly for the risk prediction of cardiovascular disease, retinopathy and nephropathy, innovative methods have been developed for prediction and tailored monitoring or treatment to prevent such complications. For other complications or subpopulations of people with type 2 diabetes, such as the frail elderly, efforts are currently ongoing to develop such methods. In this review, we discuss the recent developments in innovations of personalised diabetes care for different complications and subpopulations of people with type 2 diabetes, their performance and modes of application in clinical practice.
Introduction
People with type 2 diabetes (T2D) have a two to fourfold increased risk of developing cardiovascular disease (CVD) and are at an increased risk of microvascular complications compared to the general population. 1 Nevertheless, there is substantial heterogeneity between people with T2D in their risk of developing such complications. Personalised medicine for people with T2D is therefore focused on the classification of those people into subpopulations that differ in their susceptibility to develop a T2D-related complication or in their response to a specific treatment or in using diagnostic tests or techniques. 2 This approach provides an opportunity for patients and healthcare providers to benefit from more targeted and effective treatments, potentially delivering more healthcare gain and improved efficiency for the healthcare system. For many people, personalised medicine takes into account genetic information and proteomic profiling. However, until now the addition of this information has not proved to be more effective in the prediction of T2D-related complications than traditional clinical factors. 3 The European Association of the Study of Diabetes, the American Diabetes Association, together with many national organisations, regularly publish updated recommendations based on the latest evidence, mostly randomised controlled trials (RCTs), for the diagnosis of T2D, the screening frequency for T2D-related complications and treatment guidelines. This standardised approach has improved T2D care. Despite this progress in T2D care, micro and macrovascular complications still form a significant risk for people with T2D. been questioned. 4 RCTs form the most important base for the guidelines, but are generally performed in younger and more healthy people with T2D. As such, there is a need to develop innovative methods to tailor current treatment according to current guidelines to specific subpopulations of people with T2D, either based on their estimated risk of developing complications or different care requirements, such as elderly people with T2D. This review aims to provide an overview of current developments of innovations in the personalised care of people with T2D.
Innovative risk stratification
Although many advances have been made in the risk stratification of the T2D population, the capability to predict accurately who will get T2D-related complications is not optimal. An earlier study showed that subgroups of people with T2D, based on distinct haemoglobin A1c (HbA1c) trajectories over time, have a different risk for microvascular complications. 5 Although such subpopulations were confirmed, 6 this approach does not allow us to predict the risk of complications at an individual level. One way to improve prediction on an individual level is the development of prediction models for the individualised risk of diabetes-related complications and the estimation of sensible screening times for people with T2D. These prediction models combine clinical features and phenotypic measures to predict specific outcomes for the individual. Genetic information can also be incorporated into these models. Many models have been developed for people with T2D, but their application in clinical practice remains limited. Ways to improve prediction at an individual level include the use of more advanced statistical models with the application of changes in risk factors over time 7 or the inclusion of novel biomarkers. In the following paragraphs, we will discuss the current methods for risk stratification and prediction for different complications for people with T2D.
Risk stratification for cardiovascular complications
Over the years many risk models have been developed to estimate the future risk of CVD among people with T2D. Van Dieren et al. performed a systematic review to identify risk models to estimate the future CVD risk for people with T2D or applicable to those with T2D. 8 They identified 45 models, of which 12 were specifically developed for people with T2D. Ten of these models were subsequently validated in three prospective T2D cohort studies. 9 That study showed that the ability of the models to identify accurately those at high CVD risk (i.e. discrimination) was moderate for all 10 prediction models, with C-statistics ranging from 0.54 (95% confidence interval (CI) 0.46-0.63) to 0.76 (95% CI 0.67-0.84). The ability of the models to quantify the risk accurately was good once the models were corrected for the prevalence of disease in each of the cohorts. In a more recent study Chowdhury et al. performed a similar systematic review and meta-analysis of prediction models for CVD in people with T2D for their performance. 10 They identified 15 CVD prediction models developed for people with diabetes and 11 models developed in a general population but validated in people with diabetes. A meta-analysis of C-statistics showed an overall pooled C-statistic of 0.67 and 0.64 for validated models developed in diabetes and in general populations, respectively ( Table 1) . Altogether both studies show that current models have only moderate performance to identify accurately those at risk with relatively little differences between models or populations in which the models were developed. 9, 10 Due to the modest performance of these models, many studies have investigated the potential of biomarkers or imaging techniques to provide added prognostic value. Generally, those studies only showed very modest improvements in predictive ability with the inclusion of these additional measurements. An example of novel biomarkers that might improve CVD risk prediction includes the N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). 11 Regarding novel measures of imaging techniques, the USE-IMT initiative, for example, showed that adding the measurement of carotid intima-media thickness to the Framingham risk score does not significantly improve predictive ability, with a net reclassification improvement of only 1.7% (95% CIÀ1.8 to 3.8). 12 Kramer et al. performed a systematic review and meta-analysis for the predictive performance of coronary artery calcification for CVD risk in people with T2D. 13 The authors showed that the finding of a coronary artery calcium score below 10 in particular may add to risk stratification by the identification of people at low risk within this high-risk population. Finally, a study by van der Leeuw et al. evaluated 23 novel biomarkers for their added prognostic performance to predict CVD in people with T2D. 14 Of these biomarkers, NT-proBNP, osteopontin, matrix metalloproteinase-3 and their combination improved CVD risk prediction in people with T2D beyond traditional risk factors. However, the proportion of people with T2D reclassified to a different risk stratum was limited.
The vast majority of risk models thus far predict the risk of CVD in terms of absolute risk to develop CVD over a time period of 5-10 years. 9,10 However, the translation of the risk estimates derived from such models to recommendations for the individual is challenging. Therefore, Berkelmans et al. developed a novel prediction algorithm to predict life-years gained without myocardial infarction or stroke in 500,000 people with T2D. 15 Predictors were age, sex, smoking, systolic blood pressure, body mass index, HbA1c, estimated glomerular filtration rate, non-high-density lipoprotein cholesterol, albuminuria, T2D duration, insulin treatment and history of CVD. Internal validation showed good discrimination with a C-statistic of 0.83 (95% CI 0.83-0.84). However, again, external validation in several independent cohorts showed a modest discrimination of only 0.64-0.65. In addition, the model also combines CVD risk predictions with relative treatment effects from trials to estimate the individual benefit from preventive treatment. Overall, this approach is promising for future innovations in personalised diabetes care and translation to individual recommendations, but improvement of the performance of these models is needed. Finally, an assessment of the impact of these models in clinical practice is urgently needed. Only two clinical trials evaluated the impact of implementing such risk stratification tools in clinical practice. Clark et al. performed a 12-month prospective controlled trial to assess the effectiveness of a comprehensive diabetes management programme that included risk stratification according to American Diabetes Association (ADA) guidelines among 370 adults with diabetes. 16 That study showed an increase in the number of people with diabetes in the low-risk category for HbA1c by 51.1%. A total of 97.4% of patients with an HbA1c greater than 8% at baseline had a change in treatment regimen. People with the highest risk of coronary heart disease decreased from 25.4% at baseline to 20.2%, while those with a blood pressure at target levels increased from 23.8% to 44.6%. Of these, 63.0% had changes in medication. Finally, a study by Hall et al. investigated the impact of documentation of the cardiovascular risk score in the medical records of 323 people with diabetes on the management of cardiovascular risk factors. 17 That study showed no differences in treatment prescriptions between the intervention and control groups. Only among people at high risk, those in the experimental group were more likely to be prescribed blood pressure and lipid-lowering drugs than those in the control group.
In conclusion, many risk scores have been developed for people with T2D, but their performance is modest in most populations. Despite this, limited studies available suggest that risk stratification may improve cardiovascular risk factors in clinical practice. However, further advances should be made in enabling the translation of such risk predictions to individual treatment recommendations in clinical care. For these reasons, the current European Association for the Study of Diabetes (EASD)/European Society of Cardiology (ESC) guideline on cardiovascular risk in people with diabetes does not advise us to use such risk scores and only recommends considering to classify people with diabetes as at very high or high risk of CVD depending on the presence of concomitant risk factors and target organ damage. 18 
Risk stratification for microvascular complications Retinopathy
A common microvascular complication of diabetes is retinopathy, affecting a quarter of the diabetes population. 19 In most countries, guidelines for diabetic eye care recommend annual or biennial screening for retinopathy, which is an effective approach in the detection of the early signs of diabetic retinopathy and providing preventive treatment. However, such screening is based on a 'one-size fits all' approach, resulting in overscreening of the majority of people with T2D. Tailored screening based on the individual risk of future retinopathy would greatly increase the efficiency of diabetic retinopathy screening. Efforts to stratify in retinopathy risk range from the categorisation of retinopathy risk based on a single variable such as the presence of the early signs of retinopathy 20 to the development of prediction models for individualised retinopathy risk. [21] [22] [23] [24] These models aim to predict various stages of retinopathy during a 5-10-year time horizon, including factors that are obtained during routine diabetes care, such as the presence of early signs of retinopathy, diabetes duration, HbA1c and systolic blood pressure. External validation was performed for five of these prediction models, which resulted in Cstatistics ranging from 0.57 (95% CI 0.51-0.63) 22 to 0.84 (0.78-0.88) 24 and showed well calibration of the models (Table 1 ). Based on the predicted retinopathy risk, one of the models additionally provided a tailored screening interval ranging from 6 months to a maximum of 5 years. Previous studies showed that this method to tailor screening frequency is safe, and reducing the average screening frequency and implementation of this model in clinical practice would reduce screening frequency by 61% compared to annual screening and 23% compared to biennial screening. 25, 26 Aiming for a further improvement of retinopathy risk stratification, novel biomarkers 27 and advances in retinal imaging and classification methods 28 have been explored. Most of the blood and retinal biomarkers were not validated in independent cohorts and their additional value in the prediction of retinopathy, beyond the traditional predictors, has not been investigated. In conclusion, models for the prediction of retinopathy well validated and calibrated have been developed for people with T2D. This has led to a tailored reduced screening interval for fundus photography already being implemented in several places in clinical practice.
Nephropathy
Diabetic nephropathy is the primary cause of chronic kidney disease (CKD) in the western world and affects over 40% of people with T2D. 29 In order to prevent CKD it is important to identify accurately those at increased risk of developing CKD in the T2D population. Therefore, the monitoring of renal function is an essential part of the management of people with T2D. In addition, risk scores to predict the risk of CKD in people with T2D can aid to identify those with a high risk of CKD. Collins et al. performed a systematic review to identify prediction models of CKD, regardless of diabetes status. 30 They identified 14 prediction models, of which one was developed in people with T2D. 31 However, eight of the other 13 prediction models included diabetes status as an important predictor of CKD, making the models applicable to the diabetes population. 30 The only study in people with diabetes included in the systematic review by Collins et al., however, did not report on the performance of the model. More recently, other prediction models for CKD in people with diabetes have also been developed. For example, a large study of over 25,000 people with diabetes by Elley et al. developed a risk score including 10 predictors showing a C-statistic of 0.89 32 (Table 1 ). In addition to these models predicting overt CKD or end-stage renal disease, other models have been developed to predict microalbuminuria in people with T2D. For example, a large study by Jardine et al. in over 7000 people with diabetes in 20 countries developed a risk score for new-onset albuminuria, but the performance of that model is only moderate, with a C-statistic of 0.65. 33 A comprehensive overview of the available risk scores for CKD in people with diabetes and their performance, however, is needed.
Another development in personalised diabetes care for CKD is the identification of biomarkers to identify or predict those at increased risk of CKD. Hellemons et al. performed a systematic review on studies reporting the validity of biomarkers to predict the onset or progression of CKD in people with T2D. 34 They identified 27 biomarkers, of which the majority was related to systemic inflammation. However, the performance of these biomarkers in terms of diagnostic or predictive accuracy is mostly not reported. 34 Finally, a urinary proteomic profile has recently been developed to identify people with diabetes at high risk of developing CKD. This proteomic profile performed well in different cohorts to detect those at high risk with C-statistics ranging from 0.77 to 0.95. 35, 36 Whether such biomarkers can aid in the initiation and guidance of treatment to prevent CKD in people with T2D is currently under investigation. 37 To conclude, among currently available risk stratification methods, several seem to be accurate in the detection of people at high risk of CKD, which should be confirmed by the validation of these methods in an external cohort of people with T2D.
The diabetic foot
In contrast to risk stratification for the risk of retinopathy fewer advances have been made in risk stratification for the risk of complications of the foot.
Nevertheless, neuropathy is a debilitating complication of T2D. People with T2D have a more than 10-fold increased risk of amputation as a consequence of neuropathy than those without. 38 Foot ulcer is an important predisposing factor, preceding approximately 85% of cases with amputation. In order to screen for foot ulcers and the increased risk of amputations, several risk stratification models have been developed. Monteiro-Soares et al. performed a systematic review to identify risk stratification systems for foot ulcers. 39 The authors identified seven prognostic risk stratification systems that were mainly developed through literature review or expert consensus. Most prediction models included the following characteristics: peripheral vascular disease, infection at the ulcer site and ulcer depth. Another systematic review and metaanalysis among 16,385 people with diabetes identified only three predictors for the model: a history of foot ulceration, an inability to feel a 10 g monofilament and the absence of any pedal pulse. 40 However, only few studies evaluated their reliability or external validity. Therefore, two subsequent studies externally validated these prognostic stratification systems. 41, 42 A first validation study among 293 people with diabetes showed areas under the receiver operating characteristic curve from 0.56 to 0.83 42 (Table 1) . A second study among 446 people with diabetes showed better performance with C-statistics above 0.70, positive predictive values below 40%, but negative predictive values above 90%. 41 However, performance of these models was particularly good for hospital settings but was much lower for community-based settings. In a community-based setting, the models showed C-statistics ranging from 0.48 (95% CI 0.15-0.80) to 0.92 (95% CI 0.88-0.95) with all but one model scoring 0.70 or below. 41 In conclusion, the risk assessment methods for complications of the foot require further external validation and improvement particularly in a community-based setting.
Personalised medicine in older people with T2D
When people get older, T2D treatment becomes more complex as a result of T2D-related complications such as comorbid diseases. Therefore older people with T2D are a specific subpopulation with specific needs. Most people with T2D aged 75 years and older have three or more comorbid diseases. 43 It is well accepted to differentiate between non-frail and frail elderly people with T2D. The reason for that is that functional status determines to a great extent the mortality risk, not much influenced by interventions of hyperglycaemia, hypertension and dyslipidaemia. Finally, T2D has a heterogeneous course. People with T2D at younger ages have a more rapid disease progression than people with a diagnosis later in life. The transition from guideline-based T2D care to personalised T2D care requires prediction models much more focused on the risks of the individual with T2D as a first step. The second step can be treatment evaluations in highrisk groups.
Several studies in people up to 75 years of age have shown that intense glycaemic control in people with T2D reduces microvascular complications after an extended period (5-9 years) of time with an increased risk of short-term complications such as hypoglycaemia and mortality. 43 In these studies people older than 75 years or with multiple comorbidities were usually excluded. Some trials attempted to enroll people aged 80 years and older. In the ACCORD trial participants of that age group had very high hypoglycaemia rates when randomly allocated to the intervention arms and the protocol was revised to exclude these older people. 44 A Japanese intervention trial aiming to compare stricter glycaemic control in older people to usual care failed to reduce HbA1c levels in the intervention group, due to concerns for hypoglycaemia. 45 Besides these observations microsimulation studies have also shown that tight glycaemic control was not beneficial and some of these studies even observed an inverse relationship between the number of comorbidities and functional impairment and the benefits of tight glycaemic control. 46, 47 In recent years the concept of frailty has been receiving increasing attention. The syndrome is theoretically defined as a clinically recognisable state of increased vulnerability resulting from aging-associated decline in reserve and function across multiple physiological systems. 48 Frail older adults experience an increased risk of adverse health outcomes. Several studies have shown that older people with T2D have a higher prevalence of frailty than people without diabetes. 49, 50 Moreover, frail people with T2D have an increased risk of adverse health outcomes such as hypoglycaemia, disability and death. 49, 51, 52 Therefore, frailty and comorbidities could confound the relationship between HbA1c and mortality through a decrease in insulin resistance. 51 In this concept of burn-out T2D, the association of low HbA1c and increased mortality in the elderly is at least partly explained by the presence of frailty. According to this theoretical concept, the presence of frailty would increase ones vulnerability to hypoglycaemia not only due to the minimised adaptation responses that is part of the frailty syndrome but also because blood sugar levels are simply lower.
Frail people with T2D and comorbidities may not benefit from tight glycaemic control. Based on observational studies, guidelines take age and comorbidities into account and accept higher glucose levels for comorbid elderly, and recommend that physicians and patients personalise the treatment based on the prognosis and preferences of the individual. 4 However, so far hardly any evidence regarding the long-term effect of de-intensifying the glucose regulation in this frail group is available. 53 A retrospective cohort study in the USA showed that the ADA guideline had not yet been implemented as diabetes control was similar regardless of comorbidity burden and frailty status. 54 So far only two randomised controlled studies have been published with personalised approaches in older people. The INTERVAL study was a European double blind placebo controlled study in people of 70 years or older in which individualised treatment targets were set based on age, baseline HbA1c, comorbidities and frailty status. 55 The study consisted of a comparison between the addition of vildagliptin with placebo to usual care and had a follow-up period of 24 weeks. It was found that safety and tolerability was similar in both groups. Later it was concluded that despite extensive training and guidance the physicians in the study did not differ from the traditional glycaemic settings and therefore did not personalise the treatment strategy. 56 The MID FRAIL study recently compared a modular intervention consisting of education, exercise and personalised metabolic targets against usual care in frail people with T2D of 70 years and older, and this was the first study to show positive functional outcomes after one year which were cost-effective. 57 In summary, it is generally accepted that metabolic control in older people should be relaxed in phase with increasing multimorbidity and frailty. However, little evidence is available on how to apply this personalised strategy in clinical practice and what the clinical outcomes are.
Conclusion
This review provides an overview of current innovations in personalised care for people with T2D. We showed that many risk stratification or risk prediction approaches have been developed for both macro and microvascular complications. Such approaches perform relatively well for retinopathy and perhaps nephropathy, but only modestly for CVD and complications of the foot. For both retinopathy and nephropathy advances have been made to apply such approaches in clinical practice to guide the frequency of monitoring or to initiate preventive treatment in high-risk people with T2D. However, further advances are needed to enable the translation of such risk predictions to individual treatment recommendations in clinical care and assess the impact of such approaches. Older, frail people with T2D form a specific subpopulation requiring more relaxed treatment. However, little is known about the effects of adapted screening and treatment goals in this subpopulation and how best to identify this subpopulation. Future studies should apply novel approaches to improve personalised care further in people with T2D by using dynamic prediction models or developing more complex algorithms including artificial intelligence to aid clinical decisionmaking. These algorithms require large datasets that include a large number of variables, such as genetic information, sociodemographic characteristics and electronic health records. In conclusion, personalised medicine is a promising innovation and will change the way services will be delivered and evaluated. Prediction models will become an important part of this. The use of observational data over a long follow-up time, the use of dynamic models and artificial intelligence opens a new way to treat people with T2D.
